DRUG · Unmapped registry intervention
Camrelizumab
Find medicine records ·
Find other trials using this name
Clinical trial
Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC
NCT04303130
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedCamrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC
Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Interventions
CamrelizumabDRUG
Sponsors & collaborators
Peking University Cancer Hospital & Institutelead sponsor
Peking University First Hospitalcollaborator
Peking University Third Hospitalcollaborator
Chinese PLA General Hospitalcollaborator
Peking Union Medical College Hospitalcollaborator
Peking University People's Hospitalcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04303130 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.